Novel Mesoporous Carbon Supports for PEMFC Catalysts

Over the past decade; a significant amount of research has been performed on novel carbon supports for use in proton exchange membrane fuel cells (PEMFCs). Specifically, carbon nanotubes, ordered mesoporous carbon, and colloid imprinted carbons have shown great promise for improving the activity and/or stability of Pt-based nanoparticle catalysts. In this work, a brief overview of these materials is given, followed by an in-depth discussion of our recent work highlighting the importance of carbon wall thickness when designing novel carbon supports for PEMFC applications. Four colloid imprinted carbons (CICs) were synthesized using a silica colloid imprinting method, with the resulting CICs having pores of 15 (CIC-15), 26 (CIC-26), 50 (CIC-50) and 80 (CIC-80) nm. These four CICs were loaded with 10 wt. % Pt and then evaluated as oxygen reduction (ORR) catalysts for use in proton exchange membrane fuel cells. To gain insight into the poorer performance of Pt/CIC-26 vs. the other three Pt/CICs, TEM tomography was performed, indicating that CIC-26 had much thinner walls (0–3 nm) than the other CICs and resulting in a higher resistance (leading to distributed potentials) through the catalyst layer during operation. This explanation for the poorer performance of Pt/CIC-26 was supported by theoretical calculations, suggesting that the internal wall thickness of these nanoporous CICs is critical to the future design of porous carbon supports

Grain Size Variations in the Murray Formation: Stratigraphic Evidence for Changing Depositional Environments in Gale Crater, Mars

International audienceThe lowermost exposure of the Murray formation in Gale crater, Mars, was interpreted as sediment deposited in an ancient lake based on data collected by the Curiosity rover. Constraining the stratigraphic extent and duration of this environment has important implications for the paleohydrology of Gale. Insights into early Martian environments and paleofluid flow velocity can be obtained from grain size in rocks. Visual inspection of grain size is not always available for rocks investigated at field sites on Mars due to limited image coverage. But grain sizes can also be estimated from the Gini Index Mean Score, a grain‐size proxy that uses point‐to‐point chemical variations in ChemCam Laser Induced Breakdown Spectroscopy data. New Gini Index Mean Score results indicate that the Murray formation is dominated by mudstones with grains smaller than the spatial resolution of all rover cameras. Intervals of fine to coarse sandstone also are present, some of which are verified using observations of grain size and sedimentary structures in associated images. Overall, results demonstrate that most of the Murray consists of mudstone, suggesting settling of grains from suspension in low energy depositional environments such as lakes. Some of the mudstones contain desiccation cracks indicating periods of drying with a lowering of lake water level. However, beds and lenses of cross‐bedded sandstones are common at specific intervals, suggesting episodes of fluvial and possibly eolian deposition. The persistence of lacustrine deposits interspersed with fluvial deposits suggests that liquid water was sustained on the Martian surface for tens of thousands to millions of years

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

BACKGROUND: B cells produce alloantibodies and activate alloreactive T cells, negatively affecting kidney transplant survival. By contrast, regulatory B cells are associated with transplant tolerance. Immunotherapies are needed that inhibit B-cell effector function, including antibody secretion, while sparing regulators and minimising infection risk. B lymphocyte stimulator (BLyS) is a cytokine that promotes B-cell activation and has not previously been targeted in kidney transplant recipients. We aimed to determine the safety and activity of an anti-BLyS antibody, belimumab, in addition to standard-of-care immunosuppression in adult kidney transplant recipients. We used an experimental medicine study design with multiple secondary and exploratory endpoints to gain further insight into the effect of belimumab on the generation of de-novo IgG and on the regulatory B-cell compartment. METHODS: We undertook a double-blind, randomised, placebo-controlled phase 2 trial of belimumab, in addition to standard-of-care immunosuppression (basiliximab, mycophenolate mofetil, tacrolimus, and prednisolone) at two centres, Addenbrooke's Hospital, Cambridge, UK, and Guy's and St Thomas' Hospital, London, UK. Participants were eligible if they were aged 18-75 years and receiving a kidney transplant and were planned to receive standard-of-care immunosuppression. Participants were randomly assigned (1:1) to receive either intravenous belimumab 10 mg per kg bodyweight or placebo, given at day 0, 14, and 28, and then every 4 weeks for a total of seven infusions. The co-primary endpoints were safety and change in the concentration of naive B cells from baseline to week 24, both of which were analysed in all patients who received a transplant and at least one dose of drug or placebo (the modified intention-to-treat [mITT] population). This trial has been completed and is registered with ClinicalTrials.gov, NCT01536379, and EudraCT, 2011-006215-56. FINDINGS: Between Sept 13, 2013, and Feb 8, 2015, of 303 patients assessed for eligibility, 28 kidney transplant recipients were randomly assigned to receive belimumab (n=14) or placebo (n=14). 25 patients (12 [86%] patients assigned to the belimumab group and 13 [93%] patients assigned to the placebo group) received a transplant and were included in the mITT population. We observed similar proportions of adverse events in the belimumab and placebo groups, including serious infections (one [8%] of 12 in the belimumab group and five [38%] of 13 in the placebo group during the 6-month on-treatment phase; and none in the belimumab group and two [15%] in the placebo group during the 6-month follow-up). In the on-treatment phase, one patient in the placebo group died because of fatal myocardial infarction and acute cardiac failure. The co-primary endpoint of a reduction in naive B cells from baseline to week 24 was not met. Treatment with belimumab did not significantly reduce the number of naive B cells from baseline to week 24 (adjusted mean difference between the belimumab and placebo treatment groups -34·4 cells per μL, 95% CI -109·5 to 40·7). INTERPRETATION: Belimumab might be a useful adjunct to standard-of-care immunosuppression in renal transplantation, with no major increased risk of infection and potential beneficial effects on humoral alloimmunity. FUNDING: GlaxoSmithKline.NIHR; Glaxo Smith Klin